Evidence map›Paper›PMID 40832306›Full record

ArticlebioRxiv : the preprint server for biology2025

Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosis.

Renyta Moses, Alexandra Indeglia, Alison S Levine, Ryan Hausler, Gregory Kelly, Sven A Miller, Isabel Anez, Melissa Heller, Rosella Delgado, Caitlin Orr and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Renyta MosesDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Alexandra IndegliaGraduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Alison S LevineDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Ryan HauslerDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Gregory KellyDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Sven A MillerCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Isabel AnezDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Melissa HellerDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Rosella DelgadoDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Caitlin OrrDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Wendy KohlmannHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Anne NaumerHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Jennie VagherHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Sophie R CahillDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Luke D MaeseHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
John KaranicolasCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Judy E GarberDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Maureen E MurphyProgram in Molecular and Cellular Oncogenesis, Wistar Institute, Philadelphia, Pennsylvania.
Kara N MaxwellDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8192-4202

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Precision approaches to refining TP53-associated cancer riskR01CA242218 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI AMOS, CHRISTOPHER I., GARBER, JUDY E. · 2019 to 2023
$8.5M
Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni SyndromeU54CA272686 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Edna Cukierman · 2022 to 2026
$8.3M
Functional Analysis of p53 Polymorphic Variants - Diversity SupplementR01CA102184 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 2005 to 2026
$7.4M
A genotype-phenotype study of tumors from patients with inherited mutations in DNA repair genesK08CA215312 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MAXWELL, KARA N · 2018 to 2022
$924k
Role of PADI4 as a key epigenetic regulator of the p53 pathway and tumor suppressionF31CA277953 · NCI · UNIVERSITY OF PENNSYLVANIA · PI INDEGLIA, ALEXANDRA · 2023 to 2024
$55k
NCI NIH HHS F31 CA277953NCI NIH HHS K08 CA215312NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA102184NCI NIH HHS R01 CA242218NCI NIH HHS U54 CA272686
6 · The paper itself

Abstract

The p53 tumor suppressor binds DNA cooperatively as a tetramer, mediated by salt-bridge interactions between p53 residues E180 and R181. Variants at the R181 residue are one of the most identified

Indexed as

Familial and hereditary cancersLi Fraumeni Syndromep53 tumor suppressorTP53

Identifiers

PMID40832306
PMCPMC12363861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.